Product Description
ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor, which aims to treat non- Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and other malignant hematological tumors as a monotherapy or in combination with BTK inhibitors and other drugs. BCL2 is an important part of apoptotic pathway and is overexpressed in a variety of hematologic malignancies. ICP-248 has anti-tumor effects by activating the endogenous mitochondrial apoptosis pathway that causes rapid cancer cell apoptosis. (Sourced from: https://www.businesswire.com/news/home/20220912005570/en/InnoCare-Announces-Approval-of-Clinical-Trial-of-BCL2-Inhibitor-ICP-248-in-China)
Mechanisms of Action: BCL2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocare Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia
Phase 2: Lymphoma
Phase 1: Acute Myeloid Leukemia|Healthy Volunteers|Oncology Hematological Unspecified|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20223018 | P1 |
Recruiting |
Oncology Unspecified|Oncology Hematological Unspecified |
None |
|
| CTR20240960 | P2 |
Recruiting |
Chronic Lymphoid Leukemia|Lymphoma |
None |
|
| CTR20242579 | P1 |
Recruiting |
Healthy Volunteers|Oncology Hematological Unspecified |
None |
|
| CTR20243870 | P1 |
Recruiting |
Acute Myeloid Leukemia |
None |
|
| ICP-CL-01201 | P1 |
Recruiting |
Oncology Hematological Unspecified|Oncology Unspecified |
2025-08-30 |
23% |
| ICP-CL-01202 | P1 |
Not yet recruiting |
Oncology Unspecified |
2027-06-25 |
12% |
| ICP-CL-01203 | P3 |
Recruiting |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2030-11-25 |
17% |
| R/R AML | P1 |
Recruiting |
Acute Myeloid Leukemia |
2027-06-01 |
23% |